Ocrelizumab Superior Relapse Control in MS – Multi-Registry Study

Here’s a summary of the key takeaways from the provided text:

* Ocrelizumab is effective at reducing relapses: The study found that ocrelizumab consistently reduced relapses and worsening associated with those relapses in multiple sclerosis patients.
* no additional benefit in progression: However, ocrelizumab didn’t show any additional benefit in slowing disease progression or improving disability compared too other effective MS treatments, when looking at progression self-reliant of relapse activity.
* Need for new treatments: the researchers suggest that simply suppressing relapses may not be enough to maximize disability benefit. There’s a critical need for treatments that directly target the progression of MS, even without relapses occurring.
* Study Details: The findings were presented at ECTRIMS 2025 in Barcelona, Spain, and were based on a multi-registry observational cohort study.